Xospata Reimbursement Marks A First For AML In England
NICE has become the first reimbursement body in Europe to appraise and recommend Astellas Pharma’s drug for relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
You may also be interested in...
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.
Janssen/Legend Biotech's ciltacabtagene autoleucel and Ipsen's palovarotene are among the latest new medicines that have been submitted for pan-EU approval.